Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty

Inclusion Criteria: * Male or female participants age between 18 and \<86 years * Able to provide informed consent, geographically stable, and able to comply with the required follow-up visits * Suspected or confirmed PJI of the knee * Well-fixed and positioned prosthesis and good condition of surrounding soft tissue (no sinus tract) * A single DAIR procedure is indicated as treatment of PJI * Agree to use contraceptives if of childbearing potential Exclusion Criteria: * Loose prosthesis or surgical treatment planned for removal of well-fixed, nonmodular implants * Anticipated to require antibiotic therapy for \>6 months after DAIR procedure * Infection spread beyond the affected knee joint (e.g., osteomyelitis) * History of a prior confirmed PJI of the affected knee, including prior DAIR or revision surgery for PJI * Two or more prior revisions in the affected joint for reasons other than infection * Epithelialized sinus tract with evidence of communication to the joint or visualization of prosthesis * Diabetes mellitus and with an A1c ≥9% within 3 months, according to medical history * History of malignant disease and having received immunosuppressive therapy, radiation therapy, or chemotherapy within the past year * Known immunodeficiency (e.g., splenectomy; sickle cell anemia; human immunodeficiency virus \[HIV\] with recent CD4 count \<200 cells/mm3; or primary humoral, bone marrow, or other transplantation)